Aldose reductase inhibition suppresses the expression of Th2 cytokines and airway inflammation in ovalbumin-induced asthma in mice

Umesh C S Yadav, Amarjit S. Naura, Leopoldo Aguilera-Aguirre, Kota Ramana, Istvan Boldogh, Sanjiv Sur, Hamid A. Boulares, Satish Srivastava

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Airway inflammation induced by reactive oxygen species-mediated activation of redox-sensitive transcription factors is the hallmark of asthma, a prevalent chronic respiratory disease. In various cellular and animal models, we have recently demonstrated that, in response to multiple stimuli, aldose reductase (AR) regulates the inflammatory signals mediated by NF-κB. Because NF-κB-mediated inflammation is a major characteristic of asthma pathogenesis, we have investigated the effect of AR inhibition on NF-κB and various inflammatory markers in cellular and animal models of asthma using primary human small airway epithelial cells and OVA-sensitized/challenged C57BL/6 mice, respectively. We observed that pharmacological inhibition or genetic ablation of AR by small interfering RNA prevented TNF-α- as well as LPS-induced apoptosis; reactive oxygen species generation; synthesis of inflammatory markers IL-6, IL-8, and PGE2; and activation of NF-κB and AP-1 in small airway epithelial cells. In OVA-challenged mice, we observed that administration of an AR inhibitor markedly reduced airway hyperresponsiveness, IgE levels, eisonophils infiltration, and release of Th2 type cytokines in the airway. Our results indicate that AR inhibitors may offer a novel therapeutic approach to treat inflammatory airway diseases such as asthma.

Original languageEnglish (US)
Pages (from-to)4723-4732
Number of pages10
JournalJournal of Immunology
Volume183
Issue number7
DOIs
StatePublished - Oct 1 2009

Fingerprint

Aldehyde Reductase
Ovalbumin
Asthma
Cytokines
Inflammation
Reactive Oxygen Species
Animal Models
Epithelial Cells
Transcription Factor AP-1
Interleukin-8
Inbred C57BL Mouse
Dinoprostone
Immunoglobulin E
Small Interfering RNA
Oxidation-Reduction
Interleukin-6
Chronic Disease
Transcription Factors
Pharmacology
Apoptosis

ASJC Scopus subject areas

  • Immunology
  • Medicine(all)

Cite this

Aldose reductase inhibition suppresses the expression of Th2 cytokines and airway inflammation in ovalbumin-induced asthma in mice. / Yadav, Umesh C S; Naura, Amarjit S.; Aguilera-Aguirre, Leopoldo; Ramana, Kota; Boldogh, Istvan; Sur, Sanjiv; Boulares, Hamid A.; Srivastava, Satish.

In: Journal of Immunology, Vol. 183, No. 7, 01.10.2009, p. 4723-4732.

Research output: Contribution to journalArticle

Yadav, Umesh C S ; Naura, Amarjit S. ; Aguilera-Aguirre, Leopoldo ; Ramana, Kota ; Boldogh, Istvan ; Sur, Sanjiv ; Boulares, Hamid A. ; Srivastava, Satish. / Aldose reductase inhibition suppresses the expression of Th2 cytokines and airway inflammation in ovalbumin-induced asthma in mice. In: Journal of Immunology. 2009 ; Vol. 183, No. 7. pp. 4723-4732.
@article{9775b39580f04f36b3d937e8b5346406,
title = "Aldose reductase inhibition suppresses the expression of Th2 cytokines and airway inflammation in ovalbumin-induced asthma in mice",
abstract = "Airway inflammation induced by reactive oxygen species-mediated activation of redox-sensitive transcription factors is the hallmark of asthma, a prevalent chronic respiratory disease. In various cellular and animal models, we have recently demonstrated that, in response to multiple stimuli, aldose reductase (AR) regulates the inflammatory signals mediated by NF-κB. Because NF-κB-mediated inflammation is a major characteristic of asthma pathogenesis, we have investigated the effect of AR inhibition on NF-κB and various inflammatory markers in cellular and animal models of asthma using primary human small airway epithelial cells and OVA-sensitized/challenged C57BL/6 mice, respectively. We observed that pharmacological inhibition or genetic ablation of AR by small interfering RNA prevented TNF-α- as well as LPS-induced apoptosis; reactive oxygen species generation; synthesis of inflammatory markers IL-6, IL-8, and PGE2; and activation of NF-κB and AP-1 in small airway epithelial cells. In OVA-challenged mice, we observed that administration of an AR inhibitor markedly reduced airway hyperresponsiveness, IgE levels, eisonophils infiltration, and release of Th2 type cytokines in the airway. Our results indicate that AR inhibitors may offer a novel therapeutic approach to treat inflammatory airway diseases such as asthma.",
author = "Yadav, {Umesh C S} and Naura, {Amarjit S.} and Leopoldo Aguilera-Aguirre and Kota Ramana and Istvan Boldogh and Sanjiv Sur and Boulares, {Hamid A.} and Satish Srivastava",
year = "2009",
month = "10",
day = "1",
doi = "10.4049/jimmunol.0901177",
language = "English (US)",
volume = "183",
pages = "4723--4732",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "7",

}

TY - JOUR

T1 - Aldose reductase inhibition suppresses the expression of Th2 cytokines and airway inflammation in ovalbumin-induced asthma in mice

AU - Yadav, Umesh C S

AU - Naura, Amarjit S.

AU - Aguilera-Aguirre, Leopoldo

AU - Ramana, Kota

AU - Boldogh, Istvan

AU - Sur, Sanjiv

AU - Boulares, Hamid A.

AU - Srivastava, Satish

PY - 2009/10/1

Y1 - 2009/10/1

N2 - Airway inflammation induced by reactive oxygen species-mediated activation of redox-sensitive transcription factors is the hallmark of asthma, a prevalent chronic respiratory disease. In various cellular and animal models, we have recently demonstrated that, in response to multiple stimuli, aldose reductase (AR) regulates the inflammatory signals mediated by NF-κB. Because NF-κB-mediated inflammation is a major characteristic of asthma pathogenesis, we have investigated the effect of AR inhibition on NF-κB and various inflammatory markers in cellular and animal models of asthma using primary human small airway epithelial cells and OVA-sensitized/challenged C57BL/6 mice, respectively. We observed that pharmacological inhibition or genetic ablation of AR by small interfering RNA prevented TNF-α- as well as LPS-induced apoptosis; reactive oxygen species generation; synthesis of inflammatory markers IL-6, IL-8, and PGE2; and activation of NF-κB and AP-1 in small airway epithelial cells. In OVA-challenged mice, we observed that administration of an AR inhibitor markedly reduced airway hyperresponsiveness, IgE levels, eisonophils infiltration, and release of Th2 type cytokines in the airway. Our results indicate that AR inhibitors may offer a novel therapeutic approach to treat inflammatory airway diseases such as asthma.

AB - Airway inflammation induced by reactive oxygen species-mediated activation of redox-sensitive transcription factors is the hallmark of asthma, a prevalent chronic respiratory disease. In various cellular and animal models, we have recently demonstrated that, in response to multiple stimuli, aldose reductase (AR) regulates the inflammatory signals mediated by NF-κB. Because NF-κB-mediated inflammation is a major characteristic of asthma pathogenesis, we have investigated the effect of AR inhibition on NF-κB and various inflammatory markers in cellular and animal models of asthma using primary human small airway epithelial cells and OVA-sensitized/challenged C57BL/6 mice, respectively. We observed that pharmacological inhibition or genetic ablation of AR by small interfering RNA prevented TNF-α- as well as LPS-induced apoptosis; reactive oxygen species generation; synthesis of inflammatory markers IL-6, IL-8, and PGE2; and activation of NF-κB and AP-1 in small airway epithelial cells. In OVA-challenged mice, we observed that administration of an AR inhibitor markedly reduced airway hyperresponsiveness, IgE levels, eisonophils infiltration, and release of Th2 type cytokines in the airway. Our results indicate that AR inhibitors may offer a novel therapeutic approach to treat inflammatory airway diseases such as asthma.

UR - http://www.scopus.com/inward/record.url?scp=70449719352&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70449719352&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.0901177

DO - 10.4049/jimmunol.0901177

M3 - Article

VL - 183

SP - 4723

EP - 4732

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 7

ER -